Clarity Pharmaceuticals Ltd has released a press release.
Co-PSMA abstract released
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Quarterly Activities/Appendix 4C Cash Flow Report
- SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting
- SECuRE trial to continue with no modifications to protocol
- Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026
- Co-PSMA abstract accepted for oral presentation at EAU
Later from Clarity Pharmaceuticals
- Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial
- SECuRE trial update
- SECuRE trial update: Another participant with undetectable PSA & negative PSMA PET
- Half Yearly Report and Accounts
- AMPLIFY trial - Target number of participants achieved
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals